The risk for AD is increased 2-3-fold in the ApoE4 heterozygous carriers and 12-fold in the homozygous ones, and each ApoE4 allele lowers the AD age of onset by approximately 5 years. This evidence concerns the gene APOE and Alzheimer disease.